A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

Part of paid clinical trials in Duarte, California.

Sponsor
Eli Lilly and Company
Study ID
NCT07101328
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • B-cell Lymphoma
  • Lymphoma, B-cell Marginal Zone
  • Lymphoma, Follicular
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Mantle Cell
  • Lymphoma, Non-Hodgkin
  • Waldenstrom Macroglobulinemia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • LY4152199 - IV — DRUG
    Administered by IV infusion

Study Details

The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.

Key Dates

First listed
Aug 3, 2025
Start date
May 28, 2026
Status verified
Jul 2026
Primary completion
Apr 30, 2027
Completion
Sep 30, 2029

Study Design

Enrollment
215 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Phase 1: Dose Escalation (Cohort A) - DLBCL and FL
    Escalating doses of LY4152199 administered intravenously (IV)
  • Experimental: Phase 1: Dose Optimization (Cohort B1) - DLBCL
    Two or more doses of LY4152199 (evaluated during dose escalation) administered IV
  • Experimental: Phase 1: Dose Optimization (Cohort B2) - FL
    Two or more doses of LY4152199 (evaluated during dose escalation) administered IV

Primary Outcome Measure

Phase 1 - Number of Participants with Dose Limiting Toxicities (DLT) of LY4152199 [ Time Frame: Cycle 1 Day 1 through Cycle 2 Day 8 (35 days) ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    1-317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Locations (23)

FacilityCityStateZIPSite coordinators
City of HopeDuarteCalifornia91010-
University of Colorado Denver - School of Medicine - Anschutz Medical CampusAuroraColorado80045-2559-
Colorado Blood Cancer InstituteDenverColorado80218-
Yale University School of Medicine - Yale Cancer CenterNew HavenConnecticut06520-8028-
The University of Chicago Medical Center (UCMC)ChicagoIllinois60637-
University of IowaIowa CityIowa52242-
University of Kansas Cancer CenterKansas CityKansas66160-
Dana-Farber Cancer InstituteBostonMassachusetts02215-
Massachusetts General HospitalBostonMassachusetts02114-
University of Michigan Comprehensive Cancer CenterAnn ArborMichigan48109-
Mayo Clinic - RochesterRochesterMinnesota55905-
Rutgers Cancer Institute of New JerseyNew BrunswickNew Jersey08903-
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer CenterNew YorkNew York10065-
New York University (NYU) Clinical Cancer CenterNew YorkNew York10016-
Weill Cornell MedicineNew YorkNew York10021-
Cleveland ClinicClevelandOhio44195-
University of Pennsylvania Abramson Cancer CenterPhiladelphiaPennsylvania19104-
SCRI Oncology PartnersNashvilleTennessee37203-
University of Texas SouthwesternDallasTexas75244-
MD Anderson Cancer CenterHoustonTexas77030-
Intermountain HealthcareSalt Lake CityUtah84111-
Swedish Cancer Institute (SCI)SeattleWashington98104-
Froedtert Hospital and the Medical College of WisconsinMilwaukeeWisconsin53226-

Find similar trials in Duarte, CA

By research site
City of Hope· Duarte, CAUniversity of Colorado Denver - School of Medicine - Anschutz Medical Campus· Aurora, COColorado Blood Cancer Institute· Denver, COYale University School of Medicine - Yale Cancer Center· New Haven, CTThe University of Chicago Medical Center (UCMC)· Chicago, ILUniversity of Iowa· Iowa City, IA

Related Studies